Advertisement

Clinical Pharmacokinetics

, Volume 11, Issue 6, pp 483–504 | Cite as

Clinical Pharmacokinetics and Pharmacodynamics of Warfarin

Understanding the Dose-Effect Relationship
  • Nicholas H. G. Holford
Review Article

Summary

The simplest complete system accounting for the time-course of changes in the prothrombin time induced by warfarin requires the combination of 4 independent models:
  1. 1.

    A pharmacokinetic model for the absorption, distribution, and elimination of warfarin. Warfarin is essentially completely absorbed, reaching a maximum plasma concentration between 2 and 6 hours. It distributes into a small volume of distribution (10 L/70kg) and is eliminated by hepatic metabolism with a very small clearance (0.2 L/h/70kg). The elimination half-life is about 35 hours.

     
  2. 2.

    A pharmacodynamic model for the effect of warfarin on the synthesis of clotting factors (prothrombin complex). Prothrombin complex synthesis is inhibited 50% at a warfarin concentration of about 1.5 mg/L. Warfarin concentrations associated with therapeutic anticoagulation are of similar magnitude.

     
  3. 3.

    A physiological model for the synthesis and degradation of the prothrombin complex. The synthesis rate is about 5%/h/70kg and the elimination half-life estimated from changes in prothrombin time is approximately 17 hours. On average it will take 3 days for the anticoagulant effect of warfarin to reach a stable value when warfarin concentrations are constant.

     
  4. 4.

    A model for the relationship between the activity of prothrombin complex and the prothrombin time. In general there is a hyperbolic relationship between these quantities. Its exact shape depends upon the method used for measuring the prothrombin time.

     

Attempts to integrate these models into a single system have used essentially the same pharmacokinetic, physiological, and prothrombin activity models. Four distinct pharmacodynamic models have been proposed: linear, log-linear, power and Emax. One might be preferred on theoretical grounds (Emax) but its performance is not clearly different from the others.

Empirical methods for warfarin dose prediction as well as those based on the combined pharmacokinetic-pharmacodynamic-physiological-prothrombin system have been proposed. Only one (which was also the first) [Sheiner 1969] has been adequately described and compared with the performance of an unaided physician. The programme compared favourably with decisions made by those physicians normally responsible for adjusting warfarin dose, but was not tested prospectively.

A sizeable body of theoretical and experimental observations has contributed to our understanding of the warfarin dose-effect relationship. It remains to be demonstrated that any alternative method is superior to the traditional empirical approach to warfarin dose adjustment.

Keywords

Warfarin Clinical Pharmacology Prothrombin Prothrombin Time Pharmacodynamic Model 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aarons L, Chan E, Rowland M, Breckenridge A, Serlin M. Relationship between vitamin K-dependent clotting factors and warfarin anticoagulation at steady state. 3rd World Conference on Clinical Pharmacology and Therapeutics, Stockholm, July 27–August 1, 1986. Abstract no. 755, p. 55, 1986Google Scholar
  2. Abbrecht PH, Huhta JC. Clinical application of a mathematical model for warfarin dosage determination. Bioengineering Program Report, University of Michigan, Ann Arbor, 1972Google Scholar
  3. Abbrecht PH, O’Leary TJ, Behrendt DM. Evaluation of a computer-assisted method for individualized anticoagulation: retrospective and prospective studies with a pharmacodynamic model. Clinical Pharmacology and Therapeutics 32: 129–136, 1982PubMedCrossRefGoogle Scholar
  4. Banfield C, O’Reilly R, Chan E, Rowland M. Phenylbutazonewarfarin interaction in man: further stereochemical and metabolic considerations. British Journal of Clinical Pharmacology 16: 669–675, 1983PubMedCrossRefGoogle Scholar
  5. Barr W. Presented at the ASHP Institute on Advanced Pharmacokinetics, Lexington, 1975Google Scholar
  6. Beal S, Sheiner LB. The NONMEM system. American Statistician 34: 118, 1980CrossRefGoogle Scholar
  7. Bjornsson TD, Meffin PJ, Swezey SE, Blaschke TF. Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction. Journal of Pharmacology and Experimental Therapeutics 210: 316–321, 1979aPubMedGoogle Scholar
  8. Bjornsson TD, Meffin PJ, Swezey SE, Blaschke TF. Effects of clofibrate and warfarin alone and in combination on the disposition of vitamin K1. Journal of Pharmacology and Experimental Therapeutics 210: 323–326, 1979bGoogle Scholar
  9. Breckenridge AM. Interindividual differences in the response to oral anticoagulants. Drugs 14: 367–375, 1977PubMedCrossRefGoogle Scholar
  10. Breckenridge AM, Orme M. Kinetics of warfarin absorption in man. Clinical Pharmacology and Therapeutics 14: 955–961, 1973PubMedGoogle Scholar
  11. Breckenridge AM, Orme M, Wesseling H, Lewis RJ, Gibbons R. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clinical Pharmacology and Therapeutics 15: 424–430, 1974PubMedGoogle Scholar
  12. Carter BL, Reinders TP, Hamilton RA. Prediction of maintenance warfarin dosage from initial patient response. Drug Intelligence and Clinical Pharmacy 17: 23–26, 1983PubMedGoogle Scholar
  13. Carter BL, Taylor JW, Reinders TP. Evaluation of two methods to predict maintenance warfarin. Drug Intelligence and Clinical Pharmacy 18: 510, 1984Google Scholar
  14. Chan E, O’Reilly R, Rowland M. Stereochemical aspects of warfarin in man: a combined pharmacokinetic-pharmacodynamic model. British Journal of Clinical Pharmacology 19: 545P, 1984aGoogle Scholar
  15. Chan E, Pegg M, Mackay AD, Cole RB, Rowland M. Stereochemical aspects of warfarin in patients receiving chronic therapy. British Journal of Clinical Pharmacology 19: 571P, 1984bGoogle Scholar
  16. Choonara IA, Haynes BP, Cholertons, Breckenridge AM, Park BK, et al. Dissociation between vitamin K1 2,3-epoxide reductase and clotting factor synthesis with warfarin. 3rd World Conference on Clinical Pharmacology and Therapeutics, Stockholm, July 27–August 1, 1986. Abstract no. 756, p. 55, 1986Google Scholar
  17. Chua LH, Dobrzanski S, Taylor P. Use of a warfarin dose prediction method. Journal of Clinical and Hospital Pharmacy 9: 253–256, 1984PubMedGoogle Scholar
  18. Coleman R, Murray W, Hong R, Mitsouka C, Daschbach M, et al. Predicting response to warfarin. Thrombosis and Haemostasis 54: 79, 1985Google Scholar
  19. Deykin D. Warfarin therapy. New England Journal of Medicine 283: 691–694, 1970aPubMedCrossRefGoogle Scholar
  20. Deykin D. ‘No-Load’ warfarin therapy. New England Journal of Medicine 283: 1346, 1970bGoogle Scholar
  21. Dickson RB, King RW, Suthers MB. Warfarin: predicting maintenance doses. Australian Journal of Hospital Pharmacy 14: 30–31, 1984Google Scholar
  22. Dobrzanski S. Predicting warfarin dosage. Journal of Clinical and Hospital Pharmacy 8: 247–250, 1983PubMedGoogle Scholar
  23. Fasco MJ, Hildebrand EF, Suttie JW. Evidence that warfarin anticoagulant action involves two distinct reductase activities. Journal of Biological Chemistry 257: 11210–11212, 1982PubMedGoogle Scholar
  24. Fasco MJ, Principe LM. R- and S-warfarin inhibition of vitamin K and vitamin K 2,3-epoxide reductase activities in the rat. Journal of Biological Chemistry 257: 4894–4901, 1982PubMedGoogle Scholar
  25. Fennerty A, Dolben J, Thomas P, Backhouse G, Bentley DP, et al. Flexible induction dose regimen for warfarin and prediction of maintenance dose. Lancet 288: 1268–1270, 1984Google Scholar
  26. Fischer AM, Dautzenberg N, Pertuiset D, Ganeval D, Houin G. Pharmacolinetics of warfarin in the nephrotic syndrome and effect on vitamin-K dependent clotting factors. Thrombosis and Haemostatis 54: 82, 1985Google Scholar
  27. Gallop PM, Lian JB, Hauschka PV. Carboxylated calcium-binding proteins and vitamin K. New England Journal of Medicine 302: 1460–1466, 1980PubMedCrossRefGoogle Scholar
  28. Gordon BM, Wiser TH, Davis RJ. Warfarin maintenance-dose prediction based upon initial anticoagulant response. Clinical Pharmacy 3: 297–299, 1984PubMedGoogle Scholar
  29. Gallus A, Jackaman J, Goodall K, Tillen J. The optimal duration of heparin treatment for venous thromboembolism. Thrombosis and Haemostasis 50: 52, 1983Google Scholar
  30. Hignite C, Uetrecht J, Tschanz C, Azarnoff D. Kinetics of R and S warfarin enantiomers. Clinical Pharmacology and Therapeutics 28: 99–105, 1980PubMedCrossRefGoogle Scholar
  31. Holford NHG. Rational warfarin dosing: a pharmacokinetic-pharmacodynamic analysis. Abstract. Clinical Pharmacology and Therapeutics 39: 199, 1986Google Scholar
  32. Holford NHG, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clinical Pharmacokinetics 6: 429–453, 1981PubMedCrossRefGoogle Scholar
  33. Hotraphinyo, K, Triggs EJ, Maybloom B, Maclaine-Cross A. Warfarin sodium: steady-state plasma levels and patient age. Clinical and Experimental Pharmacology and Physiology 5: 143–149, 1978PubMedCrossRefGoogle Scholar
  34. Husted S, Andreasen F. The influence of age on the response to anticoagulants. British Journal of Clinical Pharmacology 4: 559–565, 1977PubMedCrossRefGoogle Scholar
  35. Hull R, Hirsh J, Jay R, Carter C, England C, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. New England Journal of Medicine 307: 1676–1681, 1982PubMedCrossRefGoogle Scholar
  36. International Committee for Standardisation in Haematology, International Committee on Thrombosis and Haemostasis. ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. Thrombosis and Haemostasis 51: 155–156, 1985Google Scholar
  37. Kelly JG, O’Malley K. Clinical pharmacokinetics of oral anticoagulants. Clinical Pharmacokinetics 4: 1–15, 1979PubMedCrossRefGoogle Scholar
  38. Kirking DM, Cohen IA, Shue ME, Hutchison TA. Relationship of age, weight and body surface area to warfarin maintenance dose requirements. Journal of Clinical and Hospital Pharmacy 10: 101–105, 1985PubMedGoogle Scholar
  39. Kirkwood TBL. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thrombosis and Haemostasis 49: 238–244, 1983PubMedGoogle Scholar
  40. Koch-Weser J, Sellers EM. Drug interactions with coumarin anticoagulants. I. New England Journal of Medicine 285: 487–498, 1971aCrossRefGoogle Scholar
  41. Koch-Weser J, Sellers EM. Drug interactions with coumarin anticoagulants. II. New England Journal of Medicine 285: 547–558, 1971bCrossRefGoogle Scholar
  42. Lewis RJ, Trager WF, Chan KK, Breckenridge A, Orme M, et al. Warfarin: stereochemical aspects of its metabolism and the interaction with phenylbutazone. Journal of Clinical Investigation 53: 1607–1617, 1974PubMedCrossRefGoogle Scholar
  43. Loeliger EA, van den Besselaar AMHP, Lewis SM. Reliability and clinical impact of the normalization of the prothrombin times in oral anticoagulant control. Thrombosis and Haemostasis 53: 148–154, 1985PubMedGoogle Scholar
  44. McGhee JR, Evans R, Wolfson PM, Dunlop S, Haspel L, et al. Predictability of the warfarin maintenance dose based on the initial response. Journal of the American Osteopathic Association 80: 335–339, 1981PubMedGoogle Scholar
  45. Miller DR, Brown MA. Predicting warfarin maintenance dosage based on initial response. American Journal of Hospital Pharmacy 36: 1351–1355, 1979PubMedGoogle Scholar
  46. Mungall D, Marshall J, Ludden TM, Hawkins DW, Crawford MH. Population kinetics of warfarin. 2nd World Conference on Clinical Pharmacology and Therapeutics, Washington DC, July 1983. Abstract No. 256, p. 44, 1983Google Scholar
  47. Mungall DR. Predicting prothrombin time response to warfarin, Biotrack Information Bulletin, Biotrack, Inc., Sunnyvale, November 1984Google Scholar
  48. Mungall D, Ludden TM, Marshall J, Crawford M, Hawkins D. Relationships between steady-state warfarin concentrations and anticoagulant effect. Clinical Pharmacokinetics 9 (Suppl. 1): 99–100, 1984aCrossRefGoogle Scholar
  49. Mungall D, Wong YY, Talbert RL, Crawford MH, Marshall J. Plasma protein binding of warfarin: methodological considerations. Journal of Pharmaceutical Sciences 73: 1000–1001, 1984bPubMedCrossRefGoogle Scholar
  50. Murray B, McWaters D, Coleman R, Ludden T, Mungall D. Pharmacodynamics of warfarin. Clinical Pharmacology and Therapeutics 37: 215, 1985Google Scholar
  51. Nagashima R, O’Reilly RA, Levy G. Kinetics of pharmacological effects in man: the anticoagulant action of warfarin. Clinical Pharmacology 10: 22–35, 1969Google Scholar
  52. O’Reilly RA, Aggeler PM. Determinants of the response to oral anticoagulant drugs in man. Pharmacological Reviews 22: 35–96, 1970PubMedGoogle Scholar
  53. O’Reilly RA. Anticoagulant, antithrombotic, and thrombolytic drugs. In Gilman AG et al. (Eds) Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 7th ed., Macmillan, New York, 1985Google Scholar
  54. O’Reilly RA, Aggeler PM. Studies on coumarin anticoagulant drugs: initiation of warfarin therapy without a loading dose. Circulation 28: 169–177, 1968CrossRefGoogle Scholar
  55. O’Reilly RA, Aggeler PM, Leong LS. Studies of the coumarin anticoagulant drugs: the pharmacodynamics of warfarin in man. Journal of Clinical Investigation 42: 1542–1551, 1963PubMedCrossRefGoogle Scholar
  56. O’Reilly RA, Trager WF, Motely CH, Howald W. Stereoselective interaction of phenylbutazone with [12C/13C] warfarin pseudoracemates in man. Journal of Clinical Investigation 65: 746–753, 1980PubMedCrossRefGoogle Scholar
  57. O’Reilly RA, Welling PG, Wagner JG. Pharmacokinetics of warfarin following intravenous administration to man. Thrombosis et Diathesis Haemorrhagica 25: 178–186, 1971PubMedGoogle Scholar
  58. Park BK, Choonara IA, Haynes BP, Breckenridge AM, Mahia RG, et al. Abnormal vitamin K metabolism in the presence of normal clotting factor activity in factory workers exposed to 4-hydroxy coumarins. British Journal of Clinical Pharmacology 21: 289–294, 1986PubMedCrossRefGoogle Scholar
  59. Park BK, Scott AK, Wilson AC, Haynes BP, Breckenridge AM. Plasma disposition of vitamin K1 in relation to anticoagulant poisoning. British Journal of Clinical Pharmacology 18: 655–662, 1984PubMedCrossRefGoogle Scholar
  60. Peck CC, Rodman JH. Analysis of clinical pharmacokinetic data for individualizing drug dosage regimens. In Evans et al. (Eds) Applied Pharmacokinetics, 2nd ed., Applied Therapeutics Inc., San Francisco, 1986Google Scholar
  61. Peck CC, Beal SL, Sheiner LB, Nichols AI. Extended least squares nonlinear regression: a possible solution to the ‘Choice of Weights’ problem in analysis of individual pharmacokinetic data. Journal of Pharmacokinetics and Biopharmaceutics 12: 545–558, 1984PubMedGoogle Scholar
  62. Penner JA, Abbrecht PH. Lack of interaction between ibuprofen and warfarin. Current Therapeutic Research 18: 862–871, 1975PubMedGoogle Scholar
  63. Peterson GM, McLean S, Jupe DML, Griffith RL, Roberts JR. A model which predicts maintenance warfarin dosage requirements from the response to a single dose. British Journal of Clinical Pharmacology 20: 177–178, 1985PubMedCrossRefGoogle Scholar
  64. Piroli RJ, Passananti GT, Shively CA, Vesell ES. Antipyrine and warfarin disposition in a patient with idiopathic hypoalbuminemia. Clinical Pharmacology and Therapeutics 30: 810–816, 1981PubMedCrossRefGoogle Scholar
  65. Porter RS, Lowenthal DT, Saris SD, Conry KC, Bies C, et al. Pharmacokinetic and pharmacodynamic analysis of warfarin in human subjects. Clinical Pharmacology and Therapeutics 37: 221, 1985Google Scholar
  66. Powers WF, Abbrecht PH, Covell DG. Systems and microcomputer approach to anticoagulant therapy. IEEE Transactions on Biomedical Engineering BME-27: 520–523, 1980CrossRefGoogle Scholar
  67. Quick AJ. Discussion. In Flynn (Ed.) Blood clotting and allied problems. Transactions of the First Conference, pp. 85–88, Josiah Macy Jr. Foundation, New York, 1948Google Scholar
  68. Routledge PA, Davies DM, Bell SM, Cavanagh JS, Rawlins MD. Predicting patient’s warfarin requirements. Lancet 2: 854–855, 1977PubMedCrossRefGoogle Scholar
  69. Routledge PA, Chapman PH, Davies DM, Rawlins MD. Factors affecting warfarin requirements. European Journal of Clinical Pharmacology 15: 319–322, 1979aPubMedCrossRefGoogle Scholar
  70. Routledge PA, Chapman PH, Davies DM, Rawlins MD. Pharmacokinetics and pharmacodynamics of warfarin at steady state. British Journal of Clinical Pharmacology 8: 243–247, 1979bPubMedCrossRefGoogle Scholar
  71. Sawyer WT. Predictability of warfarin dose requirements: Theoretical considerations. Journal of Pharmaceutical Sciences 68: 432–434, 1979PubMedCrossRefGoogle Scholar
  72. Sawyer WT. Warfarin. In Mungall (Ed.) Applied Clinical Pharmacokinetics, pp. 187–222, Raven Press, 1983Google Scholar
  73. Sawyer WT, Finn AL. Digital computer-assisted warfarin therapy: Comparison of two models. Computers and Biomedical Research 12: 221–231, 1979PubMedCrossRefGoogle Scholar
  74. Sawyer WT, Raasch RH. Effect of heparin on prothrombin time. Clinical Pharmacy 3: 192–194, 1984PubMedGoogle Scholar
  75. Schulman S, Lockner D, Bergstrom K, Blomback M. Intensive initial oral anticoagulation and shorter heparin treatment in deep vein thrombosis. Thrombosis and Haemostasis 52: 276–280, 1984PubMedGoogle Scholar
  76. Sharma NK, Routledge PA, Rawlins MD, Davies DM. Predicting the dose of warfarin for therapeutic anticoagulation. Thrombosis and Haemostasis 47: 230–231, 1982PubMedGoogle Scholar
  77. Sheiner LB. Computer-aided long term anticoagulation therapy. Computers and Biomedical Research 2: 519–536, 1969CrossRefGoogle Scholar
  78. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. Journal of Pharmacokinetics and Biopharmaceutics 9: 503–512, 1981PubMedGoogle Scholar
  79. Sheiner LB, Beal SL. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. Journal of Pharmaceutical Sciences 71: 1344–1348, 1982PubMedCrossRefGoogle Scholar
  80. Shepherd AMM, Hewick DS, Moreland TA, Stevenson IH. Age as a determinant of sensitivity to warfarin. British Journal of Clinical Pharmacology 4: 315–320, 1977PubMedCrossRefGoogle Scholar
  81. Shepherd AMM, Wilson N, Stevenson IH. Warfarin sensitivity in the elderly. In Crooks & Stevenson (Eds) Drugs and the elderly, University Park Press, Baltimore, 1979Google Scholar
  82. Slattery JT, Levy G, Jain A, McMahon FG. Effect of naproxen on the kinetics of elimination and anticoagulant activity of a single dose of warfarin. Clinical Pharmacology and Therapeutics 25: 51–60, 1979aPubMedGoogle Scholar
  83. Slattery JT, Levy G, Jain A, McMahon FG. Effect of naproxen on the steady-state serum concentration and anticoagulant activity of warfarin. Clinical Pharmacology and Therapeutics 25: 61–66, 1979bPubMedGoogle Scholar
  84. Smith LH. Hemorrhagic diseases. In Page & Culver (Eds) Syllabus of laboratory examinations in clinical diagnosis, p. 199, Harvard University Press, Harvard, 1961Google Scholar
  85. Spaethe R, Strauss J. The determination of the international sensitivity index (ISI) for conversion of prothrombin time (PT) into international normalized ratio (INR). Comparative studies with high and low factor sensitive thromboplastins. Thrombosis and Haemostasis 54: 80, 1985Google Scholar
  86. Stirling Y, Howarth DJ, Stockley R, Bland R, Towler CM, et al. Comparison of the bioavailabilities and anticoagulant activities of two warfarin formulations. British Journal of Haematology 51: 37–45, 1982PubMedCrossRefGoogle Scholar
  87. Svec JM, Coleman RW, Mungall DR, Ludden TM. Bayesian pharmacokinetic/pharmacodynamic forecasting of prothrombin response to warfarin therapy: preliminary evaluation. Therapeutic Drug Monitoring 7: 174–180, 1985PubMedCrossRefGoogle Scholar
  88. Theofanous TG, Barile RG. Multiple-dose kinetics of oral anticoagulants: methods of analysis and optimized dosing. Journal of Pharmaceutical Sciences 62: 261–266, 1973PubMedCrossRefGoogle Scholar
  89. Thomas P, Fennerty A, Backhouse G, Bentley DP, Campbell IA, et al. Monitoring effects of oral anticoagulants during treatment with heparin. British Medical Journal 288: 191, 1984PubMedCrossRefGoogle Scholar
  90. Toon S, Hopkins KJ, Garstang FM, Digret B, Rowland M. The warfarin-cimetidine interaction: stereochemical considerations. British Journal of Clinical Pharmacology 21: 245–246, 1986PubMedCrossRefGoogle Scholar
  91. Udall JA. ‘No-Load’ warfarin therapy. New England Journal of Medicine 283: 1345–1346, 1970PubMedGoogle Scholar
  92. van den Besselaar AMHP, Broekmans AW, Hoekstra-Schuman M, Jansen-Gruter R, Loeliger EA. Thromboplastin-dependent variation of the normalized prothrombin time (INR) in orally anticoagulated patients. Abstract. Thrombosis and Haemostasis 54: 80, 1985Google Scholar
  93. Weiner B, Faraci PA, Fayad R, Swanson L. Warfarin dosage following prosthetic valve replacement: effect of smoking history. Drug Intelligence and Clinical Pharmacy 18: 904–906, 1984PubMedGoogle Scholar
  94. Wessler S, Gitel SN. Warfarin: from bedside to bench. New England Journal of Medicine 311: 645–652, 1984PubMedCrossRefGoogle Scholar
  95. Whi Hon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry 17: 1371–1377, 1978CrossRefGoogle Scholar
  96. Wiegman H, Vossepoel AM. A computer program for long term anticoagulation control. Computer Programs in Biomedicine 7: 71–84, 1977PubMedCrossRefGoogle Scholar
  97. Williams DB, Karl RC. A simple technic for predicting daily maintenance dose of warfarin. American Journal of Surgery 137: 572–576, 1979PubMedCrossRefGoogle Scholar
  98. Wingard LB, O’Reilly RA, Levy G. Pharmacokinetics of warfarin enantiomers: a search for intrasubject correlations. Clinical Pharmacology and Therapeutics 23: 212–217, 1978PubMedGoogle Scholar
  99. Yacobi A, Udall JA, Levy G. Intrasubject variation of warfarin binding to protein in serum of patients with cardiovascular disease. Clinical Pharmacology and Therapeutics 20: 300–303, 1976PubMedGoogle Scholar

Copyright information

© ADIS Press Limited 1986

Authors and Affiliations

  • Nicholas H. G. Holford
    • 1
  1. 1.Department of Pharmacology and Clinical Pharmacology, School of MedicineUniversity of AucklandAucklandNew Zealand

Personalised recommendations